This trial is testing whether adding CBD to current treatment for psychosis can improve symptoms, cognition, and inflammation.
- Early Psychosis
5 Primary · 2 Secondary · Reporting Duration: Week 7
2 Treatment Groups
1 of 2
1 of 2
120 Total Participants · 2 Treatment Groups
Primary Treatment: Cannabidiol oral solution · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 16 - 30 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are the individuals in this research project restricted to those over 30 years old?
"This trial is looking for enrollees between the ages of 16-30. In contrast, there are 130 similar studies available for patients under 18 and 329 for those above 65." - Anonymous Online Contributor
Are people still being accepted into the trial program?
"Yes, this is an ongoing recruitment according to the information detailed on clinicaltrials.gov. The listing for this trial was created on July 1st 2021 and edited June 4th 2021." - Anonymous Online Contributor
What is the FDA's opinion on Cannabidiol oral solution?
"Cannabidiol oral solution has received a Phase 3 designation, meaning that while there is some efficacy data available, the primary focus is on safety." - Anonymous Online Contributor
How large is the scope of this clinical trial?
"That is correct. The online information regarding this study confirms that it is still recruiting patients. This particular trial was first advertised on July 1st, 2021 and the most recent update was June 4th, 2021. They are looking for a total of 120 individuals at 2 locations." - Anonymous Online Contributor
What are some other examples of research done on Cannabidiol oral solution?
"83 different clinical trials are currently underway to study the effects of Cannabidiol oral solution. This includes 18 Phase 3 trials. While many of these studies hail from Ribeirao Preto and Sao Paulo, 311 locations worldwide are participating in research for Cannabidiol oral solution." - Anonymous Online Contributor
What are the requirements to become a participant in this clinical trial?
"This trial is looking for 120 individuals, all of whom must meet the following criteria: Aged between 16 and 30, currently have a mental disorder, clinically stable for at least 2 months, first episode psychosis participants will have been maintained on current antipsychotic for at least 6 weeks with no change in antipsychotic dose for the previous 4 weeks while APS participants will be on the same treatment regimen (psychosocial or pharmacologic) for 4 weeks, exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤ 4) on PANSS items P1 (delusions), P2 (conceptual disorganization)," - Anonymous Online Contributor